

**HHS PUBLIC ACCESS**

Author manuscript

J Bone Miner Res. Author manuscript; available in PMC 2019 June 09.

Published in final edited form as:

J Bone Miner Res. 2018 November ; 33(11): 1940–1947. doi:10.1002/jbmr.3550.**Serum 25-hydroxyvitamin D and intact parathyroid hormone influences muscle outcomes in children and adolescents****Christian S Wright¹, Emma M Laing¹, Norman K Pollock², Dorothy B Hausman¹, Connie M Weaver³, Berdine R Martin³, George P McCabe⁴, Munro Peacock⁵, Stuart J Warden⁶, Kathleen Hill Gallant^{3,5}, and Richard D Lewis¹**¹Department of Foods and Nutrition, University of Georgia, Athens, GA²The Department of Pediatrics, Georgia Health Sciences University, Augusta, GA³Department of Nutrition Science, Purdue University, West Lafayette, IN⁴Department of Statistics, Purdue University, West Lafayette, IN⁵Department of Medicine, Indiana University School of Medicine, Indianapolis, IN⁶Department of Physical Therapy, Indiana University School of Health and Rehabilitation Sciences, Indianapolis, IN**Abstract**

Increases in 25-hydroxyvitamin D concentrations are shown to improve muscle strength in adults; however, data in pediatric populations are scant and equivocal. In this ancillary study of a larger-scale, multi-sited, double-blind, randomized, placebo-controlled vitamin D intervention in US children and adolescents, we examined the associations between changes in vitamin D metabolites and changes in muscle mass, strength, and composition following 12-weeks of vitamin D₃ supplementation. Healthy male and female, black and white children and adolescents between the ages of 9-13 years old from two US states (Georgia 34°N and Indiana 40°N) were enrolled in the study and randomly assigned to receive an oral vitamin D₃ dose of 0, 400, 1,000, 2,000 or 4,000 IU/d for 12 weeks between the winter months of 2009 to 2011 (N=324). Analyses of covariance, partial correlations, and regression analyses of baseline and 12-week changes (post-baseline) in vitamin D metabolites (serum 25(OH)D, 1,25(OH)₂D, intact parathyroid hormone (iPTH)) and outcomes of muscle mass, strength, and composition (total body fat-free soft tissue (FFST), handgrip strength, forearm and calf muscle cross-sectional area (MCSA), muscle density, and intermuscular adipose tissue (IMAT)) were assessed. Serum 25(OH)D and 1,25(OH)₂D, but not iPTH, increased over time, as did fat mass, FFST, forearm and calf MCSA, forearm IMAT, and handgrip strength (p<0.05). Vitamin D metabolites were not associated with muscle strength at baseline nor following the 12-week intervention. Changes in serum 25(OH)D correlated with decreases in forearm IMAT, while changes in serum iPTH predicted increases in forearm and calf

Corresponding author and person to whom reprint requests should be addressed: Richard D. Lewis, PhD, RD, FACSM, University of Georgia Foundation Professor in Family and Consumer Sciences, The University of Georgia, Department of Foods and Nutrition, 279 Dawson Hall, 305 Sanford Drive, Athens, GA, 30602., Phone: 706-542-4901, Fax: 706-542-5059, rlewis@fcs.uga.edu.

Clinical Trials Registration Number: NCT00931580

Disclosure Statement: The authors have no disclosures.

MCSA and IMAT ($p < 0.05$). Overall, increases in 25(OH)D did not influence muscle mass or strength in vitamin D sufficient children and adolescents; however, the role of iPTH on muscle composition in this population is unknown and warrants further investigation.

Keywords

Vitamin D; muscle health; pediatrics; parathyroid hormone; muscle composition

Introduction

Vitamin D insufficiency (< 50 nmol/L) is highly prevalent amongst older adults⁽¹⁾ and is becoming more commonly documented in children⁽²⁾. Classically, vitamin D plays an essential role in calcium regulation and bone metabolism, and vitamin D insufficiency is associated with low bone mass and an increased risk of skeletal fracture⁽³⁾. However, over the past few decades there has been increased interest in the non-skeletal effects of vitamin D. Muscle has been of particular interest as vitamin D deficiency (< 20 nmol/L) is associated with proximal limb myopathy⁽⁴⁾ and vitamin D insufficiency with impaired muscle function⁽⁵⁾.

Older adults with low circulating 25-hydroxyvitamin D (25(OH)D), indicative of vitamin D insufficiency, have decreased muscle strength and poor muscle function illustrated by decreased thigh muscle strength⁽⁶⁾ and power⁽⁷⁾, weak handgrip strength⁽⁸⁾, reduced gait speed⁽⁶⁾, and a prolonged sit-to-stand time⁽⁹⁾. In adolescents, lower circulating 25(OH)D has likewise been associated with decreased muscle strength and poor muscle function⁽¹⁰⁻¹²⁾. Though vitamin D supplementation is shown to improve muscle-related outcomes in adults⁽¹³⁾, only two randomized clinically controlled trials have examined this relationship in adolescents^(14,15). In the first study, vitamin D insufficient (35 nmol/L) Lebanese adolescent females ($N=168$, aged 10-17 years) were supplemented with weekly oral vitamin D₃ doses of 1,400 IU, 14,000 IU or placebo for one year. Following the intervention, significant increases in total body lean muscle mass were observed in pre-menarcheal, but not post-menarcheal females⁽¹⁴⁾. In the second study, a group of predominately vitamin D deficient (18 nmol/L) South Asian adolescent females ($N=69$, aged 12-14 years) received an oral vitamin D₂ dose of 150,000 IU or placebo every three months for one year. Following the intervention, an improvement in movement efficiency, indicating an improvement in flexibility and neuromuscular coordination, was observed⁽¹⁵⁾.

The two previously described trials were limited to adolescent females with insufficient or deficient baseline 25(OH)D concentrations and were predominately in those of Middle Eastern or South Asian ancestry. Whether increasing serum 25(OH)D concentrations improves muscle-related outcomes in vitamin D sufficient (>50 nmol/l) children and adolescents, of both sexes, is unknown. Additionally, no studies to date have examined the relationship between 25(OH)D and muscle mass, strength, or composition in black children or adolescents, which is particularly relevant given their high prevalence of low serum circulating 25(OH)D concentrations⁽¹⁶⁾. Therefore, the purpose of this ancillary analysis of a 12-week randomized, placebo-controlled vitamin D intervention was to determine if changes

in vitamin D metabolites were associated with changes in muscle-related outcomes including size, strength, and composition in black and white, male and female children and adolescents. We hypothesized that increases in circulating 25(OH)D concentrations would improve muscle-related outcomes following the 12-week intervention.

Materials and Methods

Study Participants and Design

Data from The University of Georgia, Purdue University, and Indiana University (GAPI) 12-week vitamin D intervention in US children ages 9 to 13 years (N=324) from two different latitudes (34°N or 40°N) were used for this ancillary study⁽¹⁷⁾. Briefly, participants were healthy white (n=159) and black (n=165), males (n=162) and females (n=162) from southern (n=161) or northern (n=163) locations who following enrollment during the winter months (October through December) of 2009 to 2010 and 2010 to 2011, when serum 25(OH)D is at its nadir, were randomly assigned to receive an oral vitamin D₃ dose of 0, 400, 1,000, 2,000 or 4,000 IU/d for 12 weeks. Pubertal status was kept consistent between participants by recruiting those with sexual maturity ratings of 2 and 3, estimated using a validated self-assessment questionnaire for genitalia or breast development in a mixed ethnic population⁽¹⁸⁻²⁰⁾. Participants taking nutritional supplements were enrolled after a 4-week washout period, and all participants agreed to not alter their dietary or physical activity patterns throughout the 12-week intervention. Additional details regarding the study participants, recruitment, blinding, randomization scheme and allocation, and participant flow were previously reported in Lewis et al.⁽¹⁷⁾

Exclusion criteria included achievement of menarche (for females), pre-existing muscle or bone disorders, growth disorders, or medications/supplements known to influence vitamin D metabolism. Serum 25(OH)D, 1,25-dihydroxyvitamin D [1,25(OH)₂D], intact parathyroid hormone (iPTH), indices of total body composition (fat-free soft tissue mass (FFST), fat mass, body fat percent), forearm and calf muscle cross-sectional area (MCSA), muscle density (MD), intermuscular adipose tissue (IMAT), and handgrip strength were assessed at baseline and following the 12-week intervention. Dietary intake and physical activity data were also collected for use as possible covariates in the analyses. Each university's Institutional Review Board on Human Subjects Research approved the current study.

Statistical power calculations were not conducted for this ancillary analysis. Original power calculations are published elsewhere and were based upon fractional calcium absorption, 25(OH)D, 1,25(OH)₂D, and iPTH, with 25(OH)D acting as the primary sample size determinant⁽¹⁷⁾. However, the allotted sample size provided the parent study more than 90% power ($\alpha=0.05$) to detect differences in 25(OH)D concentrations among the five-supplementation groups with forty-eight participants per group. Retrospectively, a 7.4% difference in total lean mass change following a +27.5 nmol/L (placebo) versus +69.9 nmol/L (2,000 IU/d) increase in 25(OH)D concentrations in 15 participants could be detected with 90% power (2-sided significance), according to a previous vitamin D supplementation trial in school children⁽¹⁴⁾.

Biochemical Analyses

Blood samples were collected following an overnight fast and left to sit for 30-60 minutes to coagulate before centrifuging at 4°C and 1,800 RPMs for 15 minutes. All samples were then prepared for storage and frozen at < -70°C until further analyses. Reference controls (kits) and internal controls (in-house pooled samples) were included with each assay run for quality control. All assays were conducted in duplicate using a block design, such that baseline and 12-week samples from the same subject were assayed at the same time using the same kit by the same investigator who was blinded to participant race, sex, and treatment. Repeat analyses were conducted if duplicate samples differed by >10%. Serum 25(OH)D was assessed using a 2-step radioimmunoassay (DIASORIN, 25 hydroxyvitamin D hydroxyvitamin D ¹²⁵I RIA kit, no.68100, Stillwater, MN, 100 tube kit). The inter- and intra-assay coefficients of variation (CV) were 5.2 – 8.7% and 5.5 – 8.2%, respectively, and analytical reliability was further monitored through laboratory participation in DEQAS (Vitamin D External Quality Assessment Scheme). Serum 1,25(OH)₂D was assessed using a 2-step radioimmunoassay (DIASORIN, 1,25-dihydroxyvitamin D ¹²⁵I RIA kit, no. 65100E, Stillwater, MN, 100 tube kit). The inter- and intra-assay CV were 12.4% to 17.6% and 11.6%, respectively. Serum iPTH was assessed using an immunoradiometric assay (DIASORIN, N-tact iPTH SP kit, no. 26100, Stillwater, MN 100 beads/kit). The inter- and intra-assay CV were 0.5 to 3.0% and 3.1 to 9.4%, respectively.

Whole Body Composition

Dual energy X-ray absorptiometry (DXA)—Total body FFST (kg), fat mass (kg) and percent body fat (%) were measured using DXA (Delphi A Hologic Inc. [University of Georgia site]; GE Healthcare Lunar iDXA, GE Medical Instruments [Purdue University site]; Hologic Discovery-W [Indiana University site]) at baseline and 12 weeks. For consistency, the same technician at each study site performed all analyses. DXA quality control for soft tissue was assured by standard protocols. Intra-class correlation coefficients (ICCs) were calculated in young females 5 to 8 years of age (n=10) scanned twice at the University of Georgia site during a 7-day period for measures of body composition (ICC 0.98). Short- and long-term DXA precision at the Purdue and Indiana University's sites demonstrates errors of less than 2%. Instruments from all three sites were cross-calibrated and study-specific conversion equations were developed to standardize the baseline and 12-week change data for whole body composition outcomes for all statistical analyses⁽²¹⁾.

Muscle Composition

Peripheral quantitative computed tomography (pQCT)—Non-dominant calf and forearm MCSA (mm²), MD (g/cm²) and intermuscular adipose tissue (IMAT, mm²) were measured at 66% of the bone length from the distal radius and tibia by pQCT (XCT-2000; Stratec Medizintechnik, Pforzheim, Germany) at baseline and 12 weeks. MCSA, MD, and IMAT were each assessed through multiple analyses of the same tomographic slice. MCSA of the forearm and calf are shown to be surrogate markers of muscle strength⁽²²⁾. To measure MCSA, both subcutaneous fat and bone area were individually quantified and subtracted from the total volume of interest. Subcutaneous fat was quantified by contour mode 1 and peel mode 1 using a threshold of 34 mg/cm³, while bone area was quantified

using a threshold of 710 mg/cm³. To assess MD, muscle bone area (MBA) and density (MBD) were first quantified and separated from adipose tissue using a threshold of 40 mg/cm³. Additional indices of bone area (BA) and bone density (BD) were further quantified using a threshold of 150 mg/cm³ and MD was calculated from the following equation: Muscle Density = ((MBD + (MBA / BA)) – BD)/((MBA – BA) / BA). To assess IMAT, defined in this manuscript as adipose tissue located beneath the fascia and in-between or inside muscle fibers, a contour mode 3 and peel mode 2 non-filtered analysis using a threshold of –101 mg/cm³ and an inner threshold of 40 mg/cm³ was used to separate total fat from muscle and bone. Subcutaneous fat (threshold –101 mg/cm³, inner threshold 40 mg/cm³) and bone marrow (threshold 710 mg/cm³, inner threshold –101 mg/cm³) were then subtracted from total fat to produce an IMAT value.

Scans with excessive motion (radius, n = 34; tibia, n = 16) were not included in any muscle analyses. Comparability of muscle data from each study site/scanner was achieved through a minimum of 20 phantom scans per scanner. Quality assurance was verified with daily phantom scans. Test-retest measurements were performed on five females, aged 18 to 24 years, to determine reliability of the pQCT at the University of Georgia site. ICCs for all pQCT measurements were calculated as ICC = 0.97⁽²³⁾. Similar reliability measures were shown at Indiana sites, with a root mean square CV of <1% for bone density, mass, and structure, and <1.5% for MCSA in 30 healthy individuals scanned six times with interim repositioning⁽²⁴⁾.

Handgrip strength—Maximum isometric strength of the non-dominant hand was assessed using a handgrip dynamometer (Jamar Plus+ Digital Hand Dynamometer; Patterson Medical, Bolingbrook, IL) by the same technician at each site at baseline and 12 weeks. Handgrip strength is a valid measurement of total body muscle strength⁽²⁵⁾ and physical fitness (speed, agility, flexibility, jumping)⁽²⁶⁾ in pediatric populations. At baseline, the technician adjusted the handle of the dynamometer for the most comfortable gripping position for each subject (1st and 2nd position for children), noted the subject specific setting, and repeated the same setting at 12 weeks. Three measurements were taken 30 seconds apart and the average of the three tests was recorded. Test-retest measurements in 11 participants (4 white males, 3 white females, 3 black males, and 1 black female) aged 9 to 13 years were conducted in a single day (3 hours apart) with a 30-second rest period between triplicate measurements and showed an average ICC for handgrip strength of ICC=0.98. The correlation coefficient of the handgrip dynamometer in assessing grip strength of the dominant and non-dominant hand in children has been reported as 0.97 (95% confidence interval: 0.95 to 0.98) and 0.95 (95% confidence interval: 0.92 to 0.96), respectively⁽²⁷⁾.

Dietary Intake & Physical Activity

Three-day food records (2 weekdays and 1 weekend day) were completed by participants and their parents at both baseline and 12 weeks to assess intakes of energy (kcal), vitamin D (IU) and calcium (mg). Three-day food records have been shown in adolescents as reliable tools for estimating energy and nutrient intakes⁽²⁸⁾. Diet records were analyzed using Food Processor SQL version 9.7.3 (ESHA Research). The three-day physical activity recalls (3DPAR, 1 weekend day and 2 weekdays)⁽²⁹⁾ were administered by a trained interviewer

and used to quantify each participant's type, duration and intensity of physical activity at baseline and 12 weeks. A metabolic equivalent (MET) value was assigned to each 30-minute time block based upon activity type, duration and level of intensity.

Statistics

The objective of this ancillary study was to determine the relationship between vitamin D metabolites (serum 25(OH)D, 1,25(OH)₂D, iPTH) and muscle-related outcomes (muscle mass, strength, and composition) both at baseline and their changes over the 12-week intervention. Therefore, the effect of vitamin D₃ dose on both independent and dependent variables were not examined. This effect of vitamin D₃ dose on vitamin D metabolites and the overall compliance to supplementation have previously been published⁽¹⁷⁾. Baseline group differences between race and sex were examined using two-way ANOVA. Changes over the 12-week intervention were determined by paired *t*-test, and a two-way ANOVA was used to determine differences in change values due to race and sex. Serum and muscle-related outcomes were expressed as continuous variables and were tested for normality by the Shapiro-Wilk and the Dixon tests to reveal a non-normal distribution for all serum and muscle-related outcomes. Therefore, a two-step power transformation was applied to satisfy the assumption of normally distributed errors⁽³⁰⁾. The presence of outliers were also noted for multiple muscle-related outcomes and removed according to the extreme studentized deviate test⁽³¹⁾. Physical activity and dietary intake did not change over the 12-week intervention and were not associated to vitamin D metabolites or muscle-related outcomes at baseline or 12-weeks. Therefore, physical activity and diet were not included as covariates in future analyses. Partial correlation analyses, adjusted for race, sex, age, and latitude, were performed to assess relationships between baseline and 12-week changes (i.e., post-pre) in vitamin D metabolites (25(OH)D, 1,25(OH)₂D, iPTH), and baseline and 12-week changes (i.e., post-pre) in muscle-related outcomes (muscle mass, strength, and composition). Multiple linear regression analyses, adjusted for race, sex, age, and latitude, were further performed to assess the effect of changes in vitamin D metabolites on changes in muscle-related outcomes. Statistical analyses were performed using the SPSS statistical package (IBM SPSS Statistics for Windows, Version 22.0 [IBM Corp: Armonk, NY]), and statistical significance was denoted upon *p*-value < 0.05.

Results

Baseline Characteristics (Table 1)

Black vs. white subjects were generally heavier, younger, and less physically active, with greater forearm and calf IMAT concentrations and lower muscle density, stronger grip strength, lower calcium intake, lower serum 25(OH)D, but higher serum iPTH and 1,25(OH)₂D concentrations. Males vs. females were older, taller, lighter for their age, displayed greater lean mass, less fat mass, larger forearms with higher IMAT concentrations, higher daily energy intakes, and lower serum 1,25(OH)₂D concentrations. Mean 25(OH)D for the overall sample at baseline was ~70 nmol/L. Subjects with serum 25(OH)D concentrations below 50 nmol/L and 30 nmol/L were 13% and 2%, respectively.

Baseline Partial Correlations

Partial correlations between baseline vitamin D metabolites and muscle-related outcomes, adjusted for covariates (age, race, sex, and latitude), are presented in Table 2. Baseline serum iPTH was positively correlated with FFST ($r=0.145, p=0.030$) and forearm MCSA ($r=0.152, p=0.022$).

12-week Changes Following Intervention (Table 3)

304 participants completed the 12-week intervention, yielding a 94% retention rate and is described in detail by Lewis et al.⁽¹⁷⁾. Weight, BMI-For-Age, fat mass, FFST, handgrip strength, forearm MCSA ($p = 0.001$) and IMAT ($p = 0.001$), as well as calf MCSA ($p = 0.025$) increased over the 12-week intervention. Mean serum 25(OH)D and 1,25(OH)₂D, but not iPTH, increased from baseline to 12 weeks ($p<0.0001$). Changes in serum and muscle-related outcomes did not differ between males and females nor whites and blacks over the 12-week intervention.

12-week Change Partial Correlations

Partial correlations for 12-week absolute changes in vitamin D metabolites and muscle-related outcomes (i.e., post-pre) are shown in Table 4. Age and race were positively correlated with changes in FFST (Age: $r=0.166, p=0.005$; Race: $r=-0.156, p=0.008$) and arm MCSA (Age: $r=0.14, p=0.019$; Race: $r=-0.128, p=0.031$). Changes in serum 25(OH)D were negatively correlated with changes in forearm IMAT ($r= -0.173, p=0.029$). Changes in serum iPTH, unadjusted or adjusted, were positively correlated with changes in forearm and calf MCSA, and forearm and calf IMAT. Neither baseline nor changes in dietary intakes of calcium and vitamin D or physical activity were associated with changes in serum vitamin D metabolites or muscle-related outcomes.

Multiple Linear Regression: Effects of vitamin D metabolites on muscle-related outcomes

Results from multiple linear regression analyses between 12-week changes in vitamin D metabolites (independent variable) and 12-week changes in muscle-related outcomes (dependent variable), adjusted for covariates (age, race, sex, and latitude), are presented in Table 5. Increases in serum iPTH predicted increases in calf MSCA ($\beta=0.180, p=0.003$), as well as forearm ($\beta=0.135, p>=0.035$) and calf IMAT ($\beta=0.135, p=0.038$). A trend was also present for serum iPTH and FFST ($\beta=0.112, p=0.054$).

Discussion

Changes in muscle mass and strength were not related to changes in 25(OH)D, despite large increases in serum 25(OH)D concentrations up to 155.7 nmol/L following the 12-week vitamin D₃ intervention. These results contradict previous vitamin D interventions in adults, where increases in serum 25(OH)D were associated with increases in muscle fiber size⁽³²⁾ and improvements in muscle strength⁽³³⁾ and power⁽³⁴⁾. In-vitro studies further support this notion showing alterations in calcium signaling pathways and myocellular gene expression following 25(OH)D or 1,25(OH)₂D exposure⁽³⁵⁻³⁷⁾. However, in agreement with the current study, improvements in serum 25(OH)D have also shown a neutral effect on muscle-related outcomes including a lack of an effect on muscle strength^(38,39), muscle function, or the risk

of falling^(40,41). Though alleviating vitamin D deficiency (<20 nmol/L) through supplementation improves muscle-related outcomes^(32-34,38,42,43), whether such effects occur in the absence of deficiency in both adolescents and adults (>20 nmol/L) is still unclear.

The current study is one of only three randomized clinically-controlled trials that examined the influence of changes in vitamin D metabolites on muscle-related outcomes in adolescents^(14,15). The study by El-Hajj Fuleihan et al.⁽¹⁴⁾ showed that increases in 25(OH)D increased total body FFST in Lebanese females, while the study by Ward et al.⁽¹⁵⁾ showed improvements in movement efficiency in a predominately South Asian female population. In contrast, the current study showed no such improvements in muscle mass or strength which may be explained by the length of the vitamin D intervention (i.e., 12-weeks vs. 12-months) and baseline vitamin D status of each study population (i.e., sufficient vs. insufficient).

Though shorter in duration in comparison to the two previous 12-month interventions^(14,15), the current study demonstrated increases in 25(OH)D, 1,25(OH)₂D, FFST, handgrip strength, and forearm and calf MCSA following the 12-week vitamin D intervention. These results are reasonable given the rapid rate of growth associated with the early stages of puberty⁽⁴⁴⁾. However, baseline 25(OH)D concentrations in the two previous interventions^(14,15) were considerably lower in comparison to the current study (i.e., average 35 nmol/L and 18 nmol/L vs. ~70 nmol/L, respectively). The lack of association between increasing serum 25(OH)D concentrations and changes in muscle mass and strength in the current study suggest that changes in muscle-related outcomes are only apparent when baseline 25(OH)D concentrations are insufficient⁽¹⁴⁾ or deficient⁽¹⁵⁾.

Akin to cross-sectional studies in adults⁽⁴⁵⁻⁴⁷⁾, increases in serum 25(OH)D were correlated with decreases in forearm IMAT over the 12-week vitamin D intervention following adjustment for race, sex, age, and latitude. The etiology of IMAT accumulation is still unknown, but is believed to be the result of impairments in mitochondrial function and muscle lipid metabolism⁽⁴⁸⁾. Vitamin D supplementation has shown to improve mitochondrial function⁽⁴⁹⁾ and regulate genes involved in lipogenesis and fatty acid metabolism⁽⁵⁰⁾, which could explain the current study results. Yet, associations between serum 25(OH)D and forearm or calf IMAT concentrations were not present following regression analyses. Therefore, though improvements in muscle composition following increases in 25(OH)D are present and plausible, further investigation is needed to confirm the current study result.

This study is among the first to report a positive relationship between iPTH and muscle-related outcomes in a pediatric population. Twelve-week changes in iPTH, after adjusting for covariates, were positively correlated with and even predicted changes in forearm and calf MCSA and IMAT; suggesting an overall bigger and fatter muscle with higher serum iPTH. In conjunction with a trend between iPTH and FFST, results from the current study mirror those in adults showing an independent association between iPTH concentrations and skeletal muscle mass⁽⁵¹⁾. However unlike adults⁽⁵²⁾, iPTH concentrations in the current study were not associated with handgrip strength. Furthermore, based upon adult data alone, the positive relationship between iPTH concentrations and IMAT would suggest poor muscle

strength⁽⁵³⁾ as well as an increased risk of diabetes in this early adolescent population⁽⁵⁴⁾. To our knowledge, there are no studies that have addressed the effect of IMAT on muscle strength in a non-diabetic adolescent population, and whether it elicits a negative effect or is simply a part of the normal growth process. Similarly, it is important to note that a transient diabetic-like state of insulin resistance occurs during early adolescence⁽⁵⁵⁾. Whether or not this diabetic-like state and potentially a iPTH-induced increase in IMAT are related is unclear. Therefore, more research is needed to clarify the role of iPTH and IMAT in early adolescent muscle and their potential interaction during the transient diabetic-like state.

Limitations of the present study include: 1) the exclusion of select muscle data due to motion artifacts in pQCT-derived images (forearm, n = 34; calf, n = 16), 2) the length of the study intervention, 3) participant's sufficient baseline vitamin D status, and the 4) lack of data on prior dietary supplement usage. Though there were significant changes in vitamin D metabolites and muscle-related outcomes following the 12-week intervention, based upon previous data in adolescents^(14,15) a longer study intervention may have generated larger changes in outcome variables. Additionally, though a unique aspect of the current study, conducting the 12-week intervention in a vitamin D deficient or insufficient population may have yielded a greater association between 25(OH)D and muscle-related outcomes, similar to previous data in adolescents^(14,15) and adults^(32-34,38,42,43). Finally, though all participants consuming dietary supplements prior to randomization completed a 4-week washout period and baseline dietary intakes were not associated with baseline or 12-week changes in any study outcome, future researchers should collect data on prior dietary supplement usage as a potential covariate in final analyses. The primary strength of this study is that it was a multi-site vitamin D intervention trial that assessed changes in muscle-related outcomes in both black and white and male and female vitamin D sufficient adolescents in the early stages of puberty. To our knowledge, this study was also the first to measure IMAT using pQCT in a pediatric population. Though a novel approach in pediatric populations, the assessment of IMAT using pQCT has previously been documented in adult populations^(54,56) and in the present study changes in IMAT concentrations were inversely correlated with changes in MD and positively correlated with changes in MCSA.

In summary, increases in 25(OH)D were correlated with decreases in forearm IMAT, whereas iPTH was positively associated and predicted changes in forearm and calf MCSA and IMAT in this diverse early adolescent population. Additional research is needed to clarify the relationship between 25(OH)D and IMAT accumulation, the influence of iPTH on muscle in early adolescence, and whether these are meaningful relationships.

ACKNOWLEDGEMENTS

RDL, CMW, EML, NKP, GPM, MP, and STW conceived and designed the experiment; RDL, CMW, EML, NKP, MP, STW, DBH, BRM, KHG, and CSW conducted the study and collected data. CSW, RDL, and GPM were involved in data analysis and interpretation. CSW and RDL wrote the manuscript and all authors provided editorial input, as well as read and gave final approval for the manuscript. CSW takes responsibility for the integrity of the data analysis. We would like to thank Ms. Ruth Gildea Taylor and Ms. Jessica Smith for their overall coordination of this project, Dr. Ashley Ferrira for her technical assistance, and the participants and their families for their commitment to furthering research.

Funding Source: Supported by NIH NICHD grant HD057126 (PI: R.D. Lewis) and USDA, CSRS, National Institute of Food and Agriculture Hatch projects GEO00797 (PI: R.D. Lewis) and GEO00798 (PI: E.M. Laing)

Abbreviations:

25(OH)D	25-hydroxyvitamin D
1,25(OH)₂D	1,25-dihydroxyvitamin D
RIA	Radioimmunoassay
iPTH	Intact Parathyroid Hormone
IRMA	Immunoradiometric Assay
DXA	Dual-energy X-ray Absorptiometry
pQCT	Peripheral Quantitative Computed Tomography
FFST	Fat-Free Soft Tissue
MCSA	Muscle Cross-Sectional Area
MD	Muscle Density
IMAT	Intermuscular Adipose Tissue

References

1. Haroon M, Regan MJ, Holick MF. Vitamin D deficiency: the time to ignore it has passed. *Int J Rheum Dis.* 10 Mar 2010;13(4):318–23. Epub 2011/01/05 2006/03/15. [PubMed: 21199466]
2. Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT. Vitamin D status: United States, 2001-2006. *NCHS Data Brief.* 3 2011(59): 1–8. Epub 2011/05/20.
3. DeLuca HF. Overview of general physiologic features and functions of vitamin D. *Am J Clin Nutr.* 12 2004;80(6 Suppl):1689S–96S. Epub 2004/12/09. [PubMed: 15585789]
4. Wolff AE, Jones AN, Hansen KE. Vitamin D and musculoskeletal health. *Nat Clin Pract Rheumatol.* 11 2008;4(11):580–8. Epub 2008/10/15. [PubMed: 18852718]
5. Ceglia L, Harris SS. Vitamin D and Its Role in Skeletal Muscle. *Calcif Tissue Int.* 9 12 2012. Epub 2012/09/13.
6. Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. *Osteoporos Int.* 11 2005; 16(11): 1425–31. Epub 2005/03/04. [PubMed: 15744449]
7. Kwon J, Suzuki T, Yoshida H, Kim H, Yoshida Y, Iwasa H. Concomitant lower serum albumin and vitamin D levels are associated with decreased objective physical performance among Japanese community-dwelling elderly. *Gerontology.* 2007;53(5):322–8. Epub 2007/05/31. [PubMed: 17536208]
8. Houston DK, Toozee JA, Davis CC, Chaves PH, Hirsch CH, Robbins JA, et al. Serum 25-hydroxyvitamin D and physical function in older adults: the Cardiovascular Health Study All Stars. *J Am Geriatr Soc.* 10 2011;59(10):1793–801. Epub 2011/11/19. [PubMed: 22091492]
9. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, Karlson EW, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. *Am J Clin Nutr.* 9 2004;80(3):752–8. Epub 2004/08/24. [PubMed: 15321818]
10. El-Hajj Fuleihan G, Nabulsi M, Choucair M, Salamoun M, Hajj Shahine C, Kizirian A, et al. Hypovitaminosis D in healthy schoolchildren. *Pediatrics.* 4 2001;107(4):E53. Epub 2001/05/23. [PubMed: 11335774]

11. Foo LH, Zhang Q, Zhu K, Ma G, Hu X, Greenfield H, et al. Low vitamin D status has an adverse influence on bone mass, bone turnover, and muscle strength in Chinese adolescent girls. *J Nutr.* 5 2009;139(5):1002–7. Epub 2009/03/27. [PubMed: 19321588]
12. Ward KA, Das G, Berry JL, Roberts SA, Rawer R, Adams JE, et al. Vitamin D status and muscle function in post-menarchal adolescent girls. *J Clin Endocrinol Metab.* 2 2009;94(2):559–63. Epub 2008/11/27. [PubMed: 19033372]
13. Michael YL, Whitlock EP, Lin JS, Fu R, O'Connor EA, Gold R. Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. *Ann Intern Med.* 12 21 2010;153(12):815–25. Epub 2010/12/22. [PubMed: 21173416]
14. El-Hajj Fuleihan G, Nabulsi M, Tamim H, Maalouf J, Salamoun M, Khalife H, et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. *J Clin Endocrinol Metab.* 2 2006;91(2):405–12. Epub 2005/11/10. [PubMed: 16278262]
15. Ward KA, Das G, Roberts SA, Berry JL, Adams JE, Rawer R, et al. A randomized, controlled trial of vitamin D supplementation upon musculoskeletal health in postmenarchal females. *J Clin Endocrinol Metab.* 10 2010;95(10):4643–51. Epub 2010/07/16. [PubMed: 20631020]
16. Mansbach JM, Ginde AA, Camargo CA Jr. Serum 25-hydroxyvitamin D levels among US children aged 1 to 11 years: do children need more vitamin D? *Pediatrics.* 11 2009;124(5):1404–10. Epub 2009/12/03. [PubMed: 19951983]
17. Lewis RD, Laing EM, Hill Gallant KM, Hall DB, McCabe GP, Hausman DB, et al. A randomized trial of vitamin D(3) supplementation in children: dose-response effects on vitamin D metabolites and calcium absorption. *J Clin Endocrinol Metab.* 12 2013;98(12):4816–25. [PubMed: 24092833]
18. Neinstein LS. Adolescent self-assessment of sexual maturation: reassessment and evaluation in a mixed ethnic urban population. *Clin Pediatr (Phila).* 8 1982;21(8):482–4. [PubMed: 7083719]
19. Malina RM, Reyes MEP, Tan SK, Little BB. Secular change in age at menarche in rural Oaxaca, southern Mexico: 1968–2000. *Annals of Human Biology.* Nov-Dec 2004;31(6):634–46. [PubMed: 15799231]
20. Tanner JM. *Growth & Adolescence* 2nd ed. Scientific B, editor. Oxford, UK:1962.
21. Warden SJ, Hill KM, Ferira AJ, Laing EM, Martin BR, Hausman DB, et al. Racial differences in cortical bone and their relationship to biochemical variables in Black and White children in the early stages of puberty. *Osteoporosis Int.* 6 2013;24(6):1869–79.
22. Rittweger J, Beller G, Ehrig J, Jung C, Koch U, Ramolla J, et al. Bone-muscle strength indices for the human lower leg. *Bone.* 8 2000;27(2):319–26. Epub 2000/07/29. [PubMed: 10913929]
23. Pollock NK, Laing EM, Baile CA, Hamrick MW, Hall DB, Lewis RD. Is adiposity advantageous for bone strength? A peripheral quantitative computed tomography study in late adolescent females. *Am J Clin Nutr.* 11 2007;86(5):1530–8. Epub 2007/11/10. [PubMed: 17991669]
24. Swinford RR, Warden SJ. Factors affecting short-term precision of musculoskeletal measures using peripheral quantitative computed tomography (pQCT). *Osteoporosis Int.* 11 2010;21(11): 1863–70. Epub 2010/01/07. [PubMed: 20052457]
25. Wind AE, Takken T, Helden PJM, Engelbert RHH. Is grip strength a predictor for total muscle strength in healthy children, adolescents, and young adults? *European Journal of Pediatrics.* 3 2010;169(3):281–7. [PubMed: 19526369]
26. Keihan Rodrigues Matsudo V, Matsudo S, Rezende L, Raso V. Handgrip strength as a predictor of physical fitness in children and adolescents 2014 1 p.
27. Molenaar HM, Zuidam JM, Selles RW, Stam HJ, Hovius SE. Age-specific reliability of two grip-strength dynamometers when used by children. *J Bone Joint Surg Am.* 5 2008;90(5):1053–9. Epub 2008/05/03. [PubMed: 18451398]
28. Bergman EA, Boyungs JC, Erickson ML. Comparison of a food frequency questionnaire and a 3-day diet record. *J Am Diet Assoc.* 10 1990;90(10):1431–3. Epub 1990/10/01. [PubMed: 2212429]
29. Pate RR, Dowda M. Validation of a 3-day physical activity recall instrument in female youth. *Pediatr Exer Sci.* 2003(15):257–65.
30. Templeton GF. A Two-Step Approach for Transforming Continuous Variables to Normal: Implications and Recommendations for IS Research. *Communications of the Association for Information Systems.* 2011;28(4).

31. Hoaglin DC, Iglewicz B, Tukey JW. Performance of Some Resistant Rules for Outlier Labeling. *J Am Stat Assoc.* 12 1986;81(396):991–9.
32. Ceglia L, Niramitmahapanya S, da Silva Morais M, Rivas DA, Harris SS, Bischoff-Ferrari H, et al. A randomized study on the effect of vitamin D(3) supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. *J Clin Endocrinol Metab.* 12 2013;98(12):E1927–35. [PubMed: 24108316]
33. Cangussu LM, Nahas-Neto J, Orsatti CL, Bueloni-Dias FN, Nahas EA. Effect of vitamin D supplementation alone on muscle function in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial. *Osteoporos Int.* 10 2015;26(10):2413–21. [PubMed: 25956283]
34. Carrillo AE, Flynn MG, Pinkston C, Markofski MM, Jiang Y, Donkin SS, et al. Impact of vitamin D supplementation during a resistance training intervention on body composition, muscle function, and glucose tolerance in overweight and obese adults. *Clinical nutrition (Edinburgh, Scotland).* 6 2013;32(3):375–81.
35. Boland RL. VDR activation of intracellular signaling pathways in skeletal muscle. *Mol Cell Endocrinol.* 12 05 2011;347(1–2):11–6. [PubMed: 21664245]
36. Girgis CM, Mokbel N, Cha KM, Houweling PJ, Abboud M, Fraser DR, et al. The Vitamin D Receptor (VDR) Is Expressed in Skeletal Muscle of Male Mice and Modulates 25-Hydroxyvitamin D (25OHD) Uptake in Myofibers. *Endocrinology.* 9 2014;155(9):3227–37. [PubMed: 24949660]
37. Hassan-Smith ZK, Jenkinson C, Smith DJ, Hernandez I, Morgan SA, Crabtree NJ, et al. 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 exert distinct effects on human skeletal muscle function and gene expression. *Plos One.* 2017;12(2):e0170665. [PubMed: 28199350]
38. Close GL, Leckey J, Patterson M, Bradley W, Owens DJ, Fraser WD, et al. The effects of vitamin D(3) supplementation on serum total 25[OH]D concentration and physical performance: a randomised dose-response study. *Br J Sports Med.* 7 2013;47(11):692–6. [PubMed: 23410885]
39. Goswami R, Vatsa M, Sreenivas V, Singh U, Gupta N, Lakshmy R, et al. Skeletal muscle strength in young Asian Indian females after vitamin D and calcium supplementation: a double-blind randomized controlled clinical trial. *J Clin Endocrinol Metab.* 12 2012;97(12):4709–16. [PubMed: 22904178]
40. Hansen KE, Johnson RE, Chambers KR, Johnson MG, Lemon CC, Vo TN, et al. Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial. *JAMA Intern Med.* 10 2015;175(10):1612–21. [PubMed: 26237520]
41. Glendenning P, Zhu K, Inderjeeth C, Howat P, Lewis JR, Prince RL. Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. *J Bone Miner Res.* 1 2012;27(1):170–6. [PubMed: 21956713]
42. Dhesei JK, Jackson SH, Bearne LM, Moniz C, Hurley MV, Swift CG, et al. Vitamin D supplementation improves neuromuscular function in older people who fall. *Age and ageing.* 11 2004;33(6):589–95. Epub 2004/10/27. [PubMed: 15501836]
43. Gupta R, Sharma U, Gupta N, Kalaivani M, Singh U, Guleria R, et al. Effect of cholecalciferol and calcium supplementation on muscle strength and energy metabolism in vitamin D-deficient Asian Indians: a randomized, controlled trial. *Clinical endocrinology.* 10 2010;73(4):445–51. Epub 2010/05/12. [PubMed: 20455886]
44. Rogol AD, Clark PA, Roemmich JN. Growth and pubertal development in children and adolescents: effects of diet and physical activity. *Am J Clin Nutr.* 8 2000;72(2 Suppl):521S–8S. Epub 2000/08/02. [PubMed: 10919954]
45. Bignotti B, Cadoni A, Martinoli C, Tagliafico A. Imaging of skeletal muscle in vitamin D deficiency. *World J Radiol.* 4 28 2014;6(4):119–24. [PubMed: 24778774]
46. Redzic M, Powell DK, Thomas DT. Vitamin D status is related to intramyocellular lipid in older adults. *Endocrine.* 12 2014;47(3):854–61. [PubMed: 24676758]
47. Gilsanz V, Kremer A, Mo AO, Wren TAL, Kremer R. Vitamin D Status and Its Relation to Muscle Mass and Muscle Fat in Young Women. *J Clin Endocr Metab.* 4 2010;95(4):1595–601. [PubMed: 20164290]

48. Addison O, Marcus RL, Lastayo PC, Ryan AS. Intermuscular fat: a review of the consequences and causes. *Int J Endocrinol.* 2014;2014:309570. [PubMed: 24527032]
49. Sinha A, Hollingsworth KG, Ball S, Cheetham T. Improving the Vitamin D Status of Vitamin D Deficient Adults Is Associated With Improved Mitochondrial Oxidative Function in Skeletal Muscle. *J Clin Endocr Metab.* 3 2013;98(3):E509–E13. [PubMed: 23393184]
50. Yin Y, Yu Z, Xia M, Luo X, Lu X, Ling W. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. *Eur J Clin Invest.* 11 2012;42(11): 1189–96. [PubMed: 22958216]
51. Passeri E, Bugiardini E, Sansone VA, Valaperta R, Costa E, Ambrosi B, et al. Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies. *Journal of the neurological sciences.* 8 15 2013;331(1–2): 132–5. [PubMed: 23809192]
52. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. *J Clin Endocrinol Metab.* 12 2003;88(12):5766–72. Epub 2003/12/13. [PubMed: 14671166]
53. Buford TW, Lott DJ, Marzetti E, Wohlge-muth SE, Vandeborne K, Pahor M, et al. Age-related differences in lower extremity tissue compartments and associations with physical function in older adults. *Exp Gerontol.* 1 2012;47(1):38–44. Epub 2011/10/22. [PubMed: 22015325]
54. Goodpaster BH, Thaete FL, Kelley DE. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. *Am J Clin Nutr.* 4 2000;71(4):885–92. Epub 2000/03/25. [PubMed: 10731493]
55. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. *Diabetes.* 11 2001;50(11): 2444–50. Epub 2001/10/27. [PubMed: 11679420]
56. Miljkovic-Gacic I, Gordon CL, Goodpaster BH, Bunker CH, Patrick AL, Kuller LH, et al. Adipose tissue infiltration in skeletal muscle: age patterns and association with diabetes among men of African ancestry. *Am J Clin Nutr.* 6 2008;87(6):1590–5. Epub 2008/06/11. [PubMed: 18541544]

Table 1.

Subject Characteristics

Variable ¹	N	Males			Females			Two-Way ANOVA		
		Overall	White	Black	White	Black	S x R	Sex (S)	Race (R)	
Age (years)	323	11.3 ± 1.2	12.3 ± 0.9	11.6 ± 1.1	10.9 ± 1.0	10.7 ± 1.0	NS ⁴	<0.001	<0.001	
Whole Body Composition										
Weight (kg)	323	47.4 ± 12.2	45.4 ± 11.0	45.5 ± 12.0	43.3 ± 8.4	46.8 ± 10.4	NS	NS	0.014	
Height (cm)	323	151 ± 9	153 ± 8	150 ± 9	149 ± 9	148 ± 8	NS	0.022	NS	
BMI-For-Age (%)	323	68.0 ± 29.2	51.6 ± 30.7	64.2 ± 28.8	66.4 ± 26.3	75.0 ± 28.3	NS	0.002	0.009	
Fat Mass (kg) ²	317	14.5 ± 6.9	12.2 ± 7.0	12.3 ± 7.8	14.6 ± 5.2	16.7 ± 6.2	NS	<0.001	NS	
Percent Body Fat ²	319	29.8 ± 9.4	27.6 ± 9.2	24.9 ± 9.6	32.7 ± 7.4	32.4 ± 7.8	NS	<0.001	NS	
Fat-Free Soft Tissue (kg) ²	315	30.0 ± 6.2	31.1 ± 5.6	29.9 ± 6.0	27.8 ± 5.2	28.3 ± 5.6	NS	0.002	NS	
Muscle Composition										
Forearm MCSA (cm ²) ³	319	21.2 ± 4.7	20.8 ± 3.8	22.4 ± 3.9	17.9 ± 3.5	21.2 ± 3.4	NS	<0.001	<0.001	
Forearm MD (mg/cm ³) ³	321	74.6 ± 13.7	81.8 ± 11.5	71.0 ± 12.7	76.8 ± 8.0	67.5 ± 14.1	NS	0.012	<0.001	
Forearm IMAT (cm ²) ³	289	2.6 ± 1.3	2.0 ± 0.9	3.3 ± 1.2	1.7 ± 0.8	2.9 ± 1.1	NS	0.043	<0.001	
Calf MCSA (cm ²) ³	315	47.9 ± 9.8	48.3 ± 9.1	46.8 ± 9.0	46.5 ± 8.6	46.1 ± 9.4	NS	NS	NS	
Calf MD (mg/cm ³) ³	318	73.3 ± 3.2	74.8 ± 2.2	72.4 ± 3.2	74.4 ± 1.8	71.5 ± 2.7	NS	NS	<0.001	
Calf IMAT (cm ²) ³	296	10.3 ± 3.6	9.5 ± 3.2	11.0 ± 3.1	9.2 ± 3.1	11.0 ± 3.9	NS	NS	0.001	
Handgrip Strength (kg)	288	18.0 ± 9.5	16.3 ± 8.5	22.8 ± 7.2	15.1 ± 7.9	20.6 ± 8.7	NS	NS	<0.001	
Dietary Intake										
Energy (kcal)	307	2001 ± 556	2092 ± 519	2035 ± 646	2010 ± 530	1885 ± 477	NS	NS	NS	
Calcium (mg)	307	901 ± 395	938 ± 420	801 ± 403	993 ± 444	860 ± 290	NS	NS	0.013	
Vitamin D (IU)	300	173 ± 123	191 ± 77	148 ± 81	152 ± 99	167 ± 100	NS	NS	NS	
Physical Activity METs(d)	304	62.2 ± 10.0	63.0 ± 9.1	60.1 ± 8.6	64.7 ± 11.0	58.2 ± 8.0	NS	NS	<0.001	
Biochemical Variables										
25(OH)D (nmol/L)	318	69.9 ± 18.5	79.8 ± 13.0	62.0 ± 15.2	80.5 ± 16.1	58.9 ± 18.2	NS	NS	<0.001	
iPTH (pg/mL)	314	26.9 ± 9.9	23.8 ± 8.8	28.2 ± 9.6	25.6 ± 8.4	30.0 ± 8.1	NS	NS	<0.001	

Variable ¹	N	Males		Females		Two-Way ANOVA			
		Overall	White	Black	White	Black	S x R	Sex (S)	Race (R)
1,25(OH) ₂ D (pg/mL)	318	55.4 ± 16.5	48.4 ± 15.3	54.2 ± 16.6	55.3 ± 14.6	59.7 ± 14.8	NS	0.004	0.019

¹ Values are Mean ± SD. White (n=159) and black (n=165), males (n=162) and females (n=162)

² Measured by dual-energy X-ray absorptiometry

³ Measured by peripheral quantitative computed tomography; MCSA, muscle cross-sectional area; MD, muscle density; IMAT, intermuscular adipose tissue

⁴ NS, Non-significant (p -value > 0.05); Statistically significant if p -value 0.05 and in bold font

Table 2.

Partial correlations of baseline serum and muscle-related measurements

Variable ²	25(OH)D (N=318) ¹			1,25(OH) ₂ D (N=318) ¹			iPTH (N=318) ¹						
	Unadjusted		Adjusted	Unadjusted		Adjusted	Unadjusted		Adjusted				
	N	r	P	r	P	r	P	r	P				
Fat-Free Soft Tissue (kg)	320	-0.12	0.038	-0.02	0.826	0.12	0.037	0.10	0.130	0.12	0.037	0.15	0.030
Handgrip Strength (kg)	303	-0.21	< 0.001	0.04	0.602	0.14	0.019	0.12	0.083	0.21	0.001	0.07	0.25
Forearm MCSA (mm ²)	321	-0.32	< 0.01	-0.02	0.826	0.13	0.028	0.12	0.270	0.23	< 0.001	0.15	0.022
Forearm MD (mg/cm ³)	321	0.34	< 0.001	0.09	0.166	-0.04	0.509	-0.03	0.620	-0.12	0.034	<0.01	0.99
Forearm IMAT (mm ²)	297	-0.33	< 0.001	-0.04	0.517	0.10	0.101	0.04	0.529	0.13	0.034	0.07	0.314
Calf MCSA (mm ²)	317	-0.13	0.026	-0.06	0.356	0.12	0.040	0.08	0.233	0.18	0.001	0.12	0.066
Calf MD (mg/cm ³)	318	0.39	< 0.01	0.11	0.103	0.01	0.934	<0.01	0.948	-0.16	0.006	<0.01	0.962
Calf IMAT (mm ²)	308	-0.21	< 0.01	-0.08	0.230	0.12	0.045	0.06	0.349	0.13	0.030	0.07	0.268

¹Partial correlations of unadjusted and adjusted (for race, sex, age, and latitude, N=223) between vitamin D metabolites and muscle-related outcomes. Statistically significant if *P* < 0.05 and in bold font. Partial Correlation Coefficient (r) displays strength of correlation. MCSA, muscle cross-sectional area; MD, muscle density; IMAT, intermuscular adipose tissue

Table 3.

12-week changes in body weight, composition, muscle and biochemical outcomes

Variable ¹	N	% Change	Paired T-Test	
			Time	
Whole Body Composition				
Weight (kg)	304	1.6 ± 2.9	3.6 ± 4.7	<0.001
BMI-For-Age (%)	304	2.2 ± 6.4	9.7 ± 27.6	<0.001
Fat Mass (kg) ²	296	0.57 ± 0.93	3.4 ± 52.2	<0.001
Fat-Free Soft Tissue (kg) ²	293	1.11 ± 0.91	1.3 ± 3.5	<0.001
Muscle Composition				
Forearm MCSA (cm ²) ³	296	0.83 ± 1.24	4.4 ± 11.8	<0.001
Forearm MD (mg/cm ³) ³	297	-0.85 ± 13.75	1.5 ± 16.4	NS
Forearm IMAT (cm ²) ³	255	11.24 ± 37.56	14.6 ± 122.5	0.001
Calf MCSA (cm ²) ³	293	0.07 ± 0.25	1.4 ± 8.2	0.025
Calf MD (mg/cm ³) ³	295	0.05 ± 0.77	-0.3 ± 6.0	NS
Calf IMAT (cm ²) ³	265	10.85 ± 102.70	3.1 ± 25.4	NS
Handgrip Strength (kg)	266	0.74 ± 2.06	1.8 ± 123.2	<0.001
Biochemical Variables				
25(OH)D (nmol/L)	294	22.37 ± 32.99	34.9 ± 55.9	<0.001
iPTH (pg/mL)	294	0.08 ± 8.46	4.9 ± 32.2	NS
1,25(OH) ₂ D (pg/mL)	299	9.92 ± 17.15	27.0 ± 53.3	<0.001

¹ Mean ± SD; = Post-Baseline values; % Change = ((Post-Baseline)/Baseline)* 100; Two-Way ANOVA revealed no differences in change values due to race and sex (*p*-value > 0.05).² Measured by dual-energy X-ray absorptiometry³ Measured by peripheral quantitative computed tomography; MCSA, muscle cross-sectional area; MD, muscle density; IMAT, intermuscular adipose tissue⁴ NS, Non-significant (*p*-value > 0.05); Statistically significant if *p*-value < 0.05 and in bold font.

Table 4.

Partial correlation of 12-week change in serum and muscle-related outcomes

Muscle Outcomes ²	N	25(OH)D (N=302) ¹			1,25(OH) ₂ D (N=302) ¹			iPTH (N=302) ¹					
		Unadjusted	r	P	Unadjusted	r	P	Unadjusted	r	P			
Fat-Free Soft Tissue (kg)	300	-0.04	0.564	-0.03	0.688	<0.01	0.975	0.03	0.718	<0.01	0.975	0.10	0.231
Handgrip Strength (kg)	285	0.04	0.585	0.02	0.841	0.07	0.270	0.10	0.214	0.05	0.439	<0.01	0.956
Forearm MCSA (mm ²)	299	0.03	0.666	-0.05	0.560	0.11	0.077	0.08	0.321	0.10	0.103	0.19	0.019
Forearm MD (mg/cm ³)	299	0.04	0.478	0.06	0.462	-0.03	0.652	0.01	0.862	0.01	0.939	0.01	0.922
Forearm IMAT (mm ²)	265	-0.05	0.487	-0.17	0.029	0.09	0.139	0.01	0.913	0.13	0.039	0.17	0.029
Calf MCSA (mm ²)	296	0.01	0.858	-0.04	0.581	0.09	0.154	-0.07	0.376	0.18	0.002	0.19	0.016
Calf MD (mg/cm ³)	296	-0.05	0.424	-0.10	0.192	0.02	0.693	0.07	0.362	-0.10	0.104	-0.07	0.414
Calf IMAT (mm ²)	280	0.06	0.386	0.04	0.612	0.03	0.678	-0.08	0.305	0.14	0.029	0.16	0.037

¹Partial correlations of unadjusted and adjusted (for race, sex, age, and latitude, N =239) between N Vitamin D metabolites and muscle-related outcomes. Statistically significant if P < 0.05 and in bold font. Partial Correlation Coefficient (r) displays strength of correlation.

²MCSA, muscle cross-sectional area; MD, muscle density; IMAT, intermuscular adipose tissue.

Table 5.

Multiple linear regression: Effect of vitamin D metabolites on muscle-related outcomes

Muscle Outcomes	N	25(OH)D (N=302)		1,25(OH) ₂ D (N=302)		iPTH (N=302)	
		Beta	p-value	Beta	p-value	Beta	p-value
Fat-Free Soft Tissue (kg)	300	-0.034	0.562	-0.003	0.954	0.112	0.054
Handgrip Strength (kg)	285	0.028	0.653	0.074	0.232	0.046	0.464
Forearm MCSA (mm ²)	299	0.025	0.678	0.102	0.086	0.097	0.101
Forearm MD (mg/cm ³)	299	0.049	0.415	-0.029	0.629	0.002	0.971
Forearm IMAT (mm ²)	265	-0.053	0.413	0.093	0.147	0.135	0.035
Calf MCSA (mm ²)	296	0.015	0.811	0.085	0.158	0.180	0.003
Calf MD (mg/cm ³)	296	-0.038	0.526	0.025	0.677	-0.101	0.090
Calf IMAT (mm ²)	280	0.065	0.323	0.024	0.707	0.135	0.038

1. = Post-Baseline values

2. Multiple linear regression controlling for race, sex, age, and latitude; Change in serum and muscle-related outcomes (post - baseline). Statistically significant if *P* < 0.05 and in bold font. Beta coefficient displays strength or influence of the independent variable over the dependent variable.

3. MCSA, muscle cross-sectional area; MD, muscle density; IMAT, intermuscular adipose tissue